Laquinimod in Phase II LEGATO-HD trial to treat Huntington's disease did not met its primary endpoint.- Active Biotech + Teva.
Active Biotech provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical Industries Ltd. The Phase II LEGATO-HD trial evaluating the safety and efficacy of laquinimod as a treatment in Huntington's disease (HD) did not meet its primary endpoint of change from baseline after 12 months of treatment, as measured by the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS). The study's secondary endpoint, reduction of brain atrophy (measured by caudate volume) was met. The safety results were similar to the expected event profile in this patient population. Study data will be fully analyzed. Teva will submit study results for presentations at future medical meetings and publication in peer-reviewed journals.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins